Panacea Biotec Ltd
NSE: PANACEABIO BSE: 531349
₹347.55
(-1.75%)
Thu, 12 Mar 2026, 02:37 am
Market Cap21.73B
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KPanacea Biotec Analysis
dividend
- Unable to calculate sustainability of dividends as Panacea Biotec has not reported any payouts.
- Unable to evaluate Panacea Biotec's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Panacea Biotec's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Panacea Biotec is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Panacea Biotec is profitable, therefore cash runway is not a concern.
- Panacea Biotec is profitable, therefore cash runway is not a concern.
- Operating cash flow is negative therefore debt is not well covered.
- Debt is not covered by short term assets, assets are 0.8x debt.
- Panacea Biotec's long term commitments exceed its cash and other short term assets.
- The level of debt compared to net worth has increased over the past 5 years (226.1% vs 281.1% today).
- Panacea Biotec's level of debt (281.1%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Panacea Biotec board of directors is over 10 years, this suggests they are a seasoned and experienced board.
- Sandeep's remuneration is lower than average for companies of similar size in India.
- Sandeep's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Panacea Biotec management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- Panacea Biotec is not covered by any analysts.
- Panacea Biotec has significant price volatility in the past 3 months.
past
- Panacea Biotec's 1-year earnings growth exceeds its 5-year average (393.7% vs 56.9%)
- Panacea Biotec has delivered over 20% year on year earnings growth in the past 5 years.
- Panacea Biotec used its assets more efficiently than the IN Biotechs industry average last year based on Return on Assets.
- Panacea Biotec's earnings growth has exceeded the Asia Biotechs industry average in the past year (393.7% vs -5.4%).
- It is difficult to establish if Panacea Biotec improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- Whilst Panacea Biotec has efficiently used shareholders’ funds last year (Return on Equity greater than 20%), this is metric is skewed due to its high level of debt.
value
- Panacea Biotec is good value based on earnings compared to the IN Biotechs industry average.
- PANACEABIO outperformed the Market in India which returned -14.5% over the past year.
- NSEI:PANACEABIO is up 36.5% outperforming the Biotechs industry which returned 18.2% over the past month.
- NSEI:PANACEABIO is up 36.5% outperforming the market in India which returned 8% over the past month.
- Panacea Biotec is overvalued based on assets compared to the IN Biotechs industry average.
- Panacea Biotec is overvalued based on earnings compared to the India market.
- PANACEABIO underperformed the Biotechs industry which returned 53.2% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800